-

Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Sales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019. The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019. The reason for the decline is due to COVID-19. The CAGR of the total sales from 2016 to 2020 is 6.24%.

As the epidemic situation improves, the overall sales in China are expected to have a recovery growth in 2021-2025. In addition, after the implementation of the "4 + 7" policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.

Cefoperazone Sodium and Sulbactam Sodium is an injectable antibiotic. The original drug is SULPERAZON, developed by Pfizer. In addition to Pfizer, the other main manufacturers in the Chinese market are Zhendong Health, Lepu Pharmaceutical, Guangzhou Baiyunshan Tianxin Pharmaceutical, and Shenzhen Lijian Pharmaceutical.

In China, the pharmaceutical sales of sample hospitals have an increase trend due to the population growth, awareness of the importance of health care, and increased aging population. Among all drug sales, the share of anti-infectives in recent years has always been at the top of the list. Therefore, the analyst predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.

Topics Covered:

  • The impact of COVID-19 on China's Cefoperazone Sodium and Sulbactam Sodium market
  • Sales value and volume of China's Cefoperazone Sodium and Sulbactam Sodium 2016-2020
  • Competitive landscape of China's Cefoperazone Sodium and Sulbactam Sodium market
  • Prices of Cefoperazone Sodium and Sulbactam Sodium in China
  • Prices of Cefoperazone Sodium and Sulbactam Sodium in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Cefoperazone Sodium and Sulbactam Sodium market
  • Prospect of China's Cefoperazone Sodium and Sulbactam Sodium market from 2021 to 2025

Key Topics Covered:

1 Relevant Concepts of Cefoperazone Sodium and Sulbactam Sodium

1.1 Indications for Cefoperazone Sodium and Sulbactam Sodium

1.2 Development of Cefoperazone Sodium and Sulbactam Sodium in China

1.3 Governmental Approval of Cefoperazone Sodium and Sulbactam Sodium in China

1.4 The Impact of COVID-19 on Cefoperazone Sodium and Sulbactam Sodium sales in China

2 Sales of Cefoperazone Sodium and Sulbactam Sodium in China, 2016-2020

2.1 Sales Value of Cefoperazone Sodium and Sulbactam Sodium

2.1.1 Overall Sales Value

2.1.2 Sales Value by Region

2.2 Sales Volume of Cefoperazone Sodium and Sulbactam Sodium

2.2.1 Overall Sales Volume

2.2.2 Sales Volume by Region

2.3 Sales of Cefoperazone Sodium and Sulbactam Sodium by Dosage Form in China, 2016-2020

2.3.1 Injection

2.3.2 Analysis of Other Dosage Forms

3 Analysis of Major Cefoperazone Sodium and Sulbactam Sodium Manufacturers in China, 2016-2020

3.1 Analysis of Market Share of Major Cefoperazone Sodium and Sulbactam Sodium Manufacturers

3.1.1 Investigation on Market Share by Sales Value

3.1.2 Investigation on Market Share by Sales volume

3.2 Pfizer Inc

3.2.1 Enterprise Profile

3.2.2 Sales of SULPERAZON (Pfizer's Cefoperazone Sodium and Sulbactam Sodium) in China

3.3 Zhendong Health Industry Group Co. Ltd.

3.3.1 Enterprise Profile

3.3.2 Sales of Musitan (Zhendong's Cefoperazone Sodium and Sulbactam Sodium) in China

3.4 Lepu Pharmaceutical Co., Ltd.

3.4.1 Enterprise Profile

3.4.2 Sales of Xinhaoxin (Lepu's Cefoperazone Sodium and Sulbactam Sodium) in China

3.5 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.

3.5.1 Enterprise Profile

3.5.2 Sales of Xinkuaixin (Tianxin's Cefoperazone Sodium and Sulbactam Sodium) in China

3.6 Shenzhen Lijian Pharmaceutical Co., Ltd.

3.6.1 Enterprise Profile

3.6.2 Sales of Lijianshu (Lijian's Cefoperazone Sodium and Sulbactam Sodium) in China

4 Prices of Cefoperazone Sodium and Sulbactam Sodium for Different Manufacturers in China, 2020-2021

4.1 Pfizer Inc (SULPERAZON)

4.2 Zhendong Health Industry Group Co. Ltd. (Musitan)

4.3 Lepu Pharmaceutical Co., Ltd. (Xinhaoxin)

4.4 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Xinkuaixin)

4.5 Shenzhen Lijian Pharmaceutical Co., Ltd. (Lijianshu)

5 Prospect of Chinese Cefoperazone Sodium and Sulbactam Sodium Drug Market, 2021-2025

5.1 Influential Factors of Chinese Cefoperazone Sodium and Sulbactam Sodium Market Development

5.1.1 The Impact of COVID-19 on Chinese Cefoperazone Sodium and Sulbactam Sodium Market

5.1.2 Market Drivers and Opportunities

5.1.3 Market Threats and Challenges

5.2 Forecast on Market Size

5.3 Forecast on Market Trend

For more information about this report visit https://www.researchandmarkets.com/r/7cmpqj

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Industry:

Research and Markets

Release Versions
English

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Poland Investment Funds and Asset Management Market Report 2026, Profiles of TFI, Pekao, Santander, PKO, Allianz, Goldman Sachs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Investment Funds and Asset Management Market in Poland, 2024-2026" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive overview of the investment funds and asset management sector in Poland. Analysis covers the main pillars of the market, including: mutual funds, insurance, and pension assets. The report also mid-term forecast of key volumes for the period 2025-2027. The data has been presented in a form of horizontal pr...

Europe Data Center Colocation Market Outlook & Forecast Report 2025-2030 Featuring Major Players - Digital Realty, Equinix, NTT DATA, Global Switch, CyrusOne, Ark Data Centres - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Europe Data Center Colocation Market - Industry Outlook & Forecast 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Europe Data Center Colocation Market was valued at USD 9.45 Billion in 2024, and is projected to reach USD 35.73 Billion by 2030, rising at a CAGR of 24.82%. The Europe data center colocation market is expected to witness cumulative investments of approximately $144.03 billion, of which, the Western Europe is slated to ac...

GCC Construction Equipment Market Research Report 2025-2030 Featuring Key Vendors - Caterpillar, Komatsu, Volvo, Hitachi, SANY, XCMG, JCB, Liebherr, Kobelco, and Zoomlion - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "GCC Construction Equipment Market Research Report 2025-2030" report has been added to ResearchAndMarkets.com's offering. The GCC Construction Equipment Market was sized at 68,499 Units in 2024, and is projected to reach 94,499 Units by 2030, rising at a CAGR of 5.51%. Governments in the UAE and Saudi Arabia continue to prioritize urban growth and diversification, with Dubai's long-term 2040 Urban Master Plan and the Saudi Vision 2030-linked mega-projects fuelling o...
Back to Newsroom